{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:11:10Z","timestamp":1765872670248,"version":"3.48.0"},"reference-count":27,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medecine for Malaria Venture","award":["PO18\/00879"],"award-info":[{"award-number":["PO18\/00879"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>As demonstrated in mathematical models, the simultaneous deployment of multiple first-line therapies (MFT) for uncomplicated malaria, using artemisinin-based combination therapies (ACTs), may extend the useful therapeutic life of the current ACTs. This is possible by reducing drug pressure and slowing the spread of resistance without putting patients\u2019 life at risk. We hypothesised that a simultaneous deployment of three different ACTs is feasible, acceptable and can achieve high coverage rate if potential barriers are properly identified and addressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We plan to conduct a quasi-experimental study in the Kaya health district in Burkina Faso. We will investigate a simultaneous deployment of three ACTs, artemether\u2013lumefantrine, pyronaridine\u2013artesunate, dihydroartesinin\u2013piperaquine, targeting three segments of the population: pregnant women, children under five and individuals aged five\u2009years and above. The study will include four overlapping phases: the formative phase, the MFT deployment phase, the monitoring and evaluation phase and the post-evaluation phase. The formative phase will help generate baseline information and develop MFT deployment tools. It will be followed by the MFT deployment phase in the study area. The monitoring and evaluation phase will be conducted as the deployment of MFT progresses. Cross-sectional surveys including desk reviews as well as qualitative and quantitative research methods will be used to assess the study outcomes. Quantitatives study outcomes will be measured using univariate, bivariate and multivariate analysis, including logistic regression and interrupted time series analysis approach. Content analysis will be performed on the qualitative data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The Health Research Ethics Committee in Burkina Faso approved the study (Clearance no. 2018-8-113). Study findings will be disseminated through feedback meetings with local communities, national workshops, oral presentations at congresses, seminars and publications in peer-reviewed scientific journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04265573\">NCT04265573<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040220","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T19:32:53Z","timestamp":1613417573000},"page":"e040220","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04265573","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-6548","authenticated-orcid":false,"given":"Mohamadou","family":"SIRIBIE","sequence":"first","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9-Marie","family":"Tchouatieu","sequence":"additional","affiliation":[{"name":"Access and Product Management, Medecine for Malaria Venture, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issiaka","family":"Soulama","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Moise Tanga","family":"Kabor\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yacouba","family":"Nombr\u00e9","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre le Paludisme, Minist\u00e8re de la Sant\u00e9, Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Hien","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Kiba Koumar\u00e9","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre le Paludisme, Minist\u00e8re de la Sant\u00e9, Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouhoun","family":"Barry","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1016-4896","authenticated-orcid":false,"given":"Adama","family":"Baguiya","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Institut de Recherche en Sciences de la Sant\u00e9 (IRSS), Kaya, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alimatou","family":"H\u00e9ma","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Dianda","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre le Paludisme, Minist\u00e8re de la Sant\u00e9, Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yacouba","family":"Savadogo","sequence":"additional","affiliation":[{"name":"Programme National de Lutte contre le Paludisme, Minist\u00e8re de la Sant\u00e9, Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seni","family":"Kouanda","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Institut de Recherche en Sciences de la San\u00e9 (IRSS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred Bewendtaor\u00e9","family":"Tiono","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sodiomon Bienvenu","family":"Sirima","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biom\u00e9dical et Sant\u00e9 Publique, Groupe de Recherche Action en Sante (GRAS), Ouagadougou, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2025121600091257000_11.2.e040220.1","unstructured":"S\u00e9cretariat G\u00e9n\u00e9ral, Minist\u00e8re de la Sante, Direction G\u00e9n\u00e9rale des Etudes et des Statistiques Sectorielles BF . Annuaire statistique 2018, 2019."},{"key":"2025121600091257000_11.2.e040220.2","unstructured":"Sant\u00e9 Mde , PNLP BF . Plan strat\u00e9gique 2016-2020 de lutte contre Le paludisme Au Burkina Faso, 2015."},{"key":"2025121600091257000_11.2.e040220.3","unstructured":"Sant\u00e9 Mdela , PNLP BF . Directives nationales de prise en charge Du paludisme Au Burkina Faso, 2017."},{"key":"2025121600091257000_11.2.e040220.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00318-7"},{"key":"2025121600091257000_11.2.e040220.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30291-5"},{"key":"2025121600091257000_11.2.e040220.6","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-70"},{"key":"2025121600091257000_11.2.e040220.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1099-7"},{"key":"2025121600091257000_11.2.e040220.8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1508606","article-title":"Four artemisinin-based treatments in African pregnant women with malaria","volume":"374","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121600091257000_11.2.e040220.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0805011"},{"key":"2025121600091257000_11.2.e040220.10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin Resistance in Plasmodium falciparum Malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121600091257000_11.2.e040220.11","unstructured":"World Health Organization GMP . Status report on artemisinin resistance [Internet], 2014. Available: https:\/\/www.who.int\/malaria\/publications\/atoz\/status_rep_artemisinin_resistance_jan2014.pdf"},{"key":"2025121600091257000_11.2.e040220.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature12876"},{"key":"2025121600091257000_11.2.e040220.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60484-X"},{"key":"2025121600091257000_11.2.e040220.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70181-0"},{"key":"2025121600091257000_11.2.e040220.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057689","article-title":"Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar","volume":"8","author":"Kyaw","year":"2013","journal-title":"PLoS One"},{"key":"2025121600091257000_11.2.e040220.16","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-355"},{"key":"2025121600091257000_11.2.e040220.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30048-8"},{"key":"2025121600091257000_11.2.e040220.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-017-1680-8","article-title":"Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin\u2013piperaquine in the South of Vietnam","volume":"16","author":"Thanh","year":"2017","journal-title":"Malar J"},{"key":"2025121600091257000_11.2.e040220.19","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.2174\/0929867324666170830103003","article-title":"New molecular targets and strategies for antimalarial discovery","volume":"26","author":"Aguiar","year":"2019","journal-title":"Curr Med Chem"},{"key":"2025121600091257000_11.2.e040220.20","doi-asserted-by":"crossref","DOI":"10.1007\/s11908-017-0579-4","article-title":"Triple combination therapy and drug Cycling-Tangential strategies for Countering artemisinin resistance","volume":"19","author":"Dipanjan","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"2025121600091257000_11.2.e040220.21","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(86)90248-8"},{"key":"2025121600091257000_11.2.e040220.22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt076"},{"key":"2025121600091257000_11.2.e040220.23","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2214-109X(15)00162-X","article-title":"Optimum population-level use of artemisinin combination therapies: a modelling study","volume":"3","author":"Nguyen","year":"2015","journal-title":"Lancet Glob Health"},{"key":"2025121600091257000_11.2.e040220.24","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-217"},{"key":"2025121600091257000_11.2.e040220.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804628105"},{"key":"2025121600091257000_11.2.e040220.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001984"},{"key":"2025121600091257000_11.2.e040220.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007871"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:09:22Z","timestamp":1765872562000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bmjopen-2020-040220"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040220","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}